Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Terminated 3Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 74Lymphoma, Follicular 20Lymphoma, Large B-Cell, Diffuse 19Neoplasms, Plasma Cell 11Lymphoma, Mantle-Cell 8Lymphoma, B-Cell, Marginal Zone 8Recurrence 7Smoldering Multiple Myeloma 6Lymphoma, B-Cell 6Leukemia, Lymphocytic, Chronic, B-Cell 6Neoplasms 5Lymphoma 5Lymphoma, Non-Hodgkin 4Burkitt Lymphoma 3Plasmacytoma 2Neuroblastoma 2Neoplasm, Residual 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Neurologic Manifestations 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, AIDS-Related 1Leukemia, Plasma Cell 1Leukemia 1Histiocytosis, Langerhans-Cell 1

Interventions

pembrolizumab 4Specimen Handling 2Nivolumab 2Biopsy 2talimogene laherparepvec 1romidepsin 1mogamulizumab 1fludarabine phosphate 1fludarabine 1duvelisib 1durvalumab 1Whole-Body Irradiation 1Valganciclovir 1Therapeutics 1Tacrolimus 1Sirolimus 1Radiotherapy 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1MEDI-570 1Lenalidomide 1Lactones 1Immunoglobulin G 1Gemcitabine 1Ganciclovir 1Foscarnet 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Mycosis Fungoides × Lenalidomide × Clear all
NCT03011814 2025-09-18

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Active not recruiting
38 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡